Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osivelotor in Sickle Cell Disease
NCT05431088Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2022
- Primary completion
- Dec 2030
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of osivelotor in sickle cell disease (SCD) (3 arms), sponsored by Pfizer. Primary endpoints: Part A Primary Endpoint at 12 weeks, Part B Primary Endpoint at 48 weeks and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05431088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431088.